Tissue-selective RNA interference in prostate cancer cell using prostate specific membrane antigen promoter/enhancer.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Urologic oncology

• Publication date

  2009-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.urolonc.2008.05.003PMID 18639471
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prostate cancer.

  2019cited by this paper
• Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells.

  2007cited by this paper
• RNA interference technologies and their use in cancer research

  2007cited by this paper
• Hormone refractory prostate cancer: Management and advances.

  2006cited by this paper
• Inhibition of Growth and Metastasis of Human Hepatocellular Carcinoma by Antisense Oligonucleotide Targeting Signal Transducer and Activator of Transcription 3

  2006cited by this paper
• Gene Therapy Progress and Prospects: Recent progress in transgene and RNAi expression cassettes

  2005cited by this paper
• Construction of prostate-specific expressed recombinant plasmids with high transcriptional activity of prostate-specific membrane antigen (PSMA) promoter/enhancer.

  2005cited by this paper
• Down-Regulation of Signal Transducer and Activator of Transcription 3 Expression Using Vector-Based Small Interfering RNAs Suppresses Growth of Human Prostate Tumor In vivo

  2005cited by this paper
• Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines.

  2004cited by this paper
• Unlocking the potential of the human genome with RNA interference

  2004cited by this paper
• RNAi Therapeutics: How Likely, How Soon?

  2004cited by this paper
• Comparison of gene expression in HCT116 treatment derivatives generated by two different 5-fluorouracil exposure protocols

  2004cited by this paper
• Gene Silencing in Androgen-Responsive Prostate Cancer Cells from the Tissue-Specific Prostate-Specific Antigen Promoter

  2004cited by this paper
• Mechanisms of androgen-refractory prostate cancer.

  2004cited by this paper
• Poly(U) and polyadenylation termination signals are interchangeable for terminating the expression of shRNA from a pol II promoter.

  2004cited by this paper
• RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells

  2004cited by this paper
• Gene silencing in alveolar type II cells using cell-specific promoter in vitro and in vivo.

  2004cited by this paper
• A DNA vector-based RNAi technology to suppress gene expression in mammalian cells

  2002cited by this paper
• Coexpression of the partial androgen receptor enhances the efficacy of prostate-specific antigen promoter-driven suicide gene therapy for prostate cancer cells at low testosterone concentrations.

  2001cited by this paper
• Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils.

  1999cited by this paper
• Gene Therapy Death Prompts Review of Adenovirus Vector

  1999cited by this paper
• A simplified system for generating recombinant adenoviruses.

  1998cited by this paper
• Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma

  1998cited by this paper
• STATs and gene regulation.

  1997cited by this paper
• Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization.

  1997cited by this paper
• Characterization of 911: A New Helper Cell Line for the Titration and Propagation of Early Region 1-Deleted Adenoviral Vectors

  1996cited by this paper
• Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy.

  1996cited by this paper
• WI‐38 cell long‐term quiescence model system: A valuable tool to study molecular events that regulate growth

  1994cited by this paper
• Expression of the prostate-specific membrane antigen.

  1994cited by this paper
• Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen.

  1993cited by this paper

• Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges

  2017cites this paper
• Cathelicidin PR-39 peptide inhibits hypoxia/reperfusion-induced kidney cell apoptosis by suppression of the endoplasmic reticulum-stress pathway.

  2016cites this paper
• Construction and detection of the tissue-specific pINV-HPV16 E6/7 vector

  2014cites this paper
• Role of Promoters and Micro RNA Backbone for Efficient Gene Silencing

  2013cites this paper
• Prostate-specific membrane antigen can promote in vivo osseous metastasis of prostate cancer cells in mice

  2012influential citation
• Cell‐selective gene silencing in prostate cancer LNCap cells using prostate‐specific membrane antigen promoter and enhancer in vitro and in vivo

  2012cites this paper
• Cell type specific, traceable gene silencing for functional gene analysis during vertebrate neural development

  2011cites this paper
• Lentivirus-mediated RNAi knockdown of prostate-specific membrane antigen suppresses growth, reduces migration ability and the invasiveness of prostate cancer cells

  2011cites this paper
• Transcriptional regulation of inducible nitric oxide synthase gene therapy: targeting early stage and advanced prostate cancer

  2010cites this paper
• Strategies for short hairpin RNA delivery in cancer gene therapy

  2009cites this paper
• Experimental animal model and RNA interference: a promising association for bladder cancer research

  2009cites this paper
• Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy.

  2009cites this paper
• Applications of RNA interference in cancer therapeutics as a powerful tool for suppressing gene expression

  2008cites this paper